H1 2026 Financial Performance Summary of 27 Global Medical Device and Diagnostics Leaders Including Medtronic, Johnson & Johnson, Siemens Healthineers, and Philips

Note: The fiscal years of major companies do not necessarily align with the calendar year, leading to discrepancies between fiscal quarters/years and their calendar counterparts. Companies may release performance results on a quarterly or semi-annual basis.

Medical Devices and Diagnostics

Medtronic Reports First-Quarter Results for the Period Ended July 31, 2026. Quarterly net sales amounted to $9.756 billion, compared to $8.578 billion in the same period last year, representing a year-over-year increase of 13.7%. Quarterly operating profit was $1.764 billion, compared to $1.445 billion in the same period last year. Quarterly net income attributable to the company was $1.47 billion, compared to $1.04 billion in the same period last year.

Johnson & Johnson Reports Second-Quarter 2026 Results. Quarterly sales reached $25.31 billion, compared to $23.743 billion in the same period last year, representing a year-over-year increase of 6.6%. Of this, Innovative Medicine sales totaled $16.384 billion, up 7.8% year over year. MedTech sales amounted to $8.926 billion, an increase of 4.5% year over year. Quarterly net income was $5.534 billion, compared to $5.537 billion in the same period last year.

Abbott Announces Second Quarter 2026 Results. Net sales for the quarter totaled $12.593 billion, compared to $11.142 billion in the same period last year, representing a 13% year-over-year increase. Operating profit for the quarter was $1.693 billion, down 17.5% from $2.052 billion in the same period last year. Net income for the quarter amounted to $928 million, a 47.8% decrease from $1.779 billion in the same period last year. By segment, net sales were $5.853 billion for Medical Devices, $3.092 billion for Diagnostics, $1.499 billion for Pharmaceutical Products, and $2.144 billion for Nutrition.

Medline Announces Second Quarter 2026 Results. Net sales for the quarter were $7.685 billion, compared to $6.886 billion in the same period last year, representing an 11.6% year-over-year increase. Operating profit for the quarter was $395 million, down 38.5% from $642 million in the same period last year. Net income attributable to the company for the quarter was $60 million, a decrease of 82% from $333 million in the same period last year.

Siemens Healthineers Announces Third-Fiscal-Quarter Results for the Period Ended June 30, 2026. Quarterly revenue amounted to €5.764 billion (approximately $6.67 billion), representing a year-on-year increase of 1.8% from €5.662 billion in the same period last year. Adjusted quarterly EBIT reached €1.101 billion, a 15.6% year-on-year increase from €953 million. Quarterly net profit totaled €676 million, marking a 21.7% year-on-year increase from €556 million.

Stryker Announces Second Quarter 2026 Financial Results. Quarterly net sales were $6.589 billion, compared to $6.022 billion in the same period last year, representing a year-over-year increase of 9.4%. Quarterly operating profit was $1.659 billion, compared to $1.113 billion in the same period last year, representing a year-over-year increase of 49.1%. Quarterly net income was $1.276 billion, compared to $884 million in the same period last year, representing a year-over-year increase of 44.3%.

Danaher Announces Second Quarter 2026 Results. Quarterly sales were $6.265 billion, compared to $5.936 billion in the same period last year. Quarterly operating profit was $1.127 billion, compared to $760 million in the same period last year. Quarterly net income was $870 million, compared to $555 million in the same period last year.

Fresenius Medical Care, the German leader in dialysis care, announces its second-quarter 2026 results. Quarterly revenue amounted to €4.861 billion (approximately $5.63 billion), compared to €4.792 billion in the same period last year. Quarterly operating profit was €466 million, up from €425 million a year earlier. Quarterly net profit stood at €218 million, compared to €225 million in the prior-year period.

Boston Scientific Announces Second Quarter 2026 Financial Results. Quarterly net sales totaled $5.442 billion, compared to $5.061 billion in the same period last year. Quarterly operating profit amounted to $1.178 billion, compared to $819 million in the same period last year. Quarterly net income attributable to common shareholders was $907 million, compared to $797 million in the same period last year.

GE HealthCare Announces Second Quarter 2026 Results. Total quarterly revenue amounted to $5.295 billion, compared to $5.007 billion in the same period last year. Quarterly operating profit reached $739 million, up from $654 million in the prior-year period. Net income attributable to the company for the quarter was $561 million, compared to $486 million in the same period last year.

Philips Announces Q2 2026 Financial Results. Quarterly sales amounted to €4.36 billion (approximately $5.05 billion), compared to €4.338 billion in the same period last year. Quarterly operating profit reached €609 million, up from €400 million in the prior-year period. Quarterly net profit stood at €386 million, compared to €240 million in the same period last year.

BD Reports Third-Quarter Fiscal 2026 Results Ended June 30, 2026Quarterly revenue totaled $4.983 billion, compared to $4.726 billion in the same period last year, representing a year-over-year increase of 5.4%. Quarterly operating profit was $663 million, down from $739 million in the prior-year period, a year-over-year decrease of 10.3%. Quarterly net income amounted to $377 million, compared to $574 million in the same period last year, marking a year-over-year decline of 34.3%.

Roche Announces First-Half 2026 ResultsThe Group’s sales for the period amounted to CHF 30.364 billion, compared to CHF 30.944 billion in the same period last year, representing a 2% year-on-year decline. IFRS operating profit was CHF 9.671 billion, down 1% from CHF 10.33 billion in the previous year. Net profit attributable to shareholders of the company stood at CHF 6.871 billion.Specifically, the Pharmaceuticals Division reported sales of CHF 23.629 billion, a 1% decrease from CHF 23.985 billion in the same period last year, with an operating profit of CHF 10.838 billion. The Diagnostics Division recorded sales of CHF 6.735 billion (approximately USD 8.286 billion), a 3% decline from CHF 6.959 billion in the previous year, with an operating profit of CHF 870 million.

Thermo Fisher Scientific Announces Second Quarter 2026 Financial ResultsQuarterly revenue totaled $11.994 billion, compared to $10.855 billion in the same period last year. Quarterly operating profit was $2.087 billion, compared to $1.834 billion in the same period last year. Net income attributable to the company for the quarter was $1.736 billion, compared to $1.617 billion in the same period last year. Revenue by segment included: Life Sciences Solutions, $2.815 billion; Laboratory Products and Biopharma Services, $6.693 billion; Specialty Diagnostics, $1.205 billion; and Analytical Instruments, $1.847 billion.

Henry Schein Announces Second Quarter 2026 Results. Quarterly net sales were $3.458 billion, compared to $3.24 billion in the same period last year. Quarterly operating profit was $171 million, compared to $151 million in the same period last year. Quarterly net income attributable to the company was $94 million, compared to $86 million in the same period last year.

Cardinal Health Reports Fourth-Quarter and Full-Year Fiscal 2026 Results Ended June 30, 2026Fourth-quarter revenue reached $63.672 billion, a 6% year-over-year increase. Net income attributable to the company for the quarter was $398 million, representing a 67% year-over-year growth. Within this, the Medical Products and Distribution segment reported revenue of $3.1 billion and profit of $150 million.Full-year fiscal 2026 revenue totaled $254.248 billion, up 14% year over year. Net income attributable to the company for the fiscal year was $1.714 billion, a 10% year-over-year increase. Of this, the Medical Products and Distribution segment generated revenue of $12.7 billion and profit of $258 million.

Baxter International Announces Second Quarter 2026 Results. Quarterly net sales amounted to $2.96 billion, compared to $2.81 billion in the same period last year, representing a 5% year-over-year increase. Quarterly operating profit reached $217 million, up from $191 million in the same period last year, a 14% year-over-year increase. Quarterly net income attributable to shareholders was $126 million, compared to $91 million in the same period last year, marking a 38% year-over-year increase.

Intuitive Surgical Reports Second Quarter 2026 Financial Results. Total quarterly revenue was $2.892 billion, compared to $2.44 billion in the same period last year. Quarterly operating profit was $972 million, compared to $855 million in the same period last year. Net income attributable to the company was $818 million, compared to $822 million in the same period last year.

Solventum Announces Second Quarter 2026 Results. Quarterly net sales were $2.209 billion, compared to $2.161 billion in the same period last year, representing a year-over-year increase of 2.2%. Quarterly net income was $92 million, compared to $90 million in the same period last year, representing a year-over-year increase of 2.2%.

Zimmer Biomet Holdings Reports Second Quarter 2026 Results. Quarterly net sales were $2.177 billion, compared to $2.077 billion in the same period last year. Quarterly operating profit was $326 million, compared to $300 million in the same period last year. Quarterly net income attributable to the company was $198 million, compared to $153 million in the same period last year.

Terumo Announces First-Quarter Financial Results for the Fiscal Year Ending June 30, 2026Terumo Corporation announced its financial results for the first quarter ended June 30, 2026. Quarterly revenue amounted to JPY 311.81 billion (approximately USD 1.96 billion), representing a 19.9% year-over-year increase from JPY 259.965 billion in the same period last year. Quarterly operating profit reached JPY 89.48 billion, a 60.1% year-over-year increase from JPY 55.885 billion in the prior year. Net income attributable to owners of the parent company totaled JPY 70.426 billion, marking a 68.3% year-over-year increase from JPY 41.843 billion in the same period last year.

Olympus Announces First Quarter Fiscal 2026 Results for the Period Ended June 30, 2026. Quarterly revenue amounted to JPY 240.4 billion (approximately USD 1.51 billion), representing a 16.4% year-on-year increase from JPY 206.512 billion in the same period of the previous year. Quarterly operating profit reached JPY 28.951 billion, a 74.4% year-on-year increase from JPY 16.597 billion in the prior year. Net income attributable to owners of the parent company for the quarter was JPY 19.102 billion, marking a 112.5% year-on-year increase from JPY 8.991 billion in the same period of the previous year.

Fujifilm Holdings Announces First Quarter Fiscal 2026 Results for the Period Ended June 30, 2026Quarterly revenue amounted to JPY 826.493 billion, compared to JPY 749.482 billion in the same period of the previous year, representing a year-on-year increase of 10.3%. Quarterly operating profit was JPY 51.184 billion, down 32% from JPY 75.291 billion in the same period of the previous year. Net income attributable to the company stood at JPY 37.424 billion, a 30.4% decrease from JPY 53.767 billion in the same period of the previous year.By business segment, the Healthcare segment generated revenue of JPY 256.8 billion (approximately USD 1.612 billion), a 12.4% year-on-year increase. The Electronic Materials segment reported revenue of JPY 127.7 billion, up 25% year-on-year. The Imaging segment recorded revenue of JPY 166.8 billion, a 16.2% year-on-year increase. The Business Innovation segment posted revenue of JPY 273.2 billion, a slight decline of 0.1% year-on-year.

Canon Group Announces First-Half 2026 Financial ResultsNet sales for the period totaled JPY 227.4542 billion, compared to JPY 219.8567 billion in the same period last year, representing a year-on-year increase of 3.5%. Operating profit for the period amounted to JPY 23.0595 billion, up 7.6% from JPY 21.4308 billion in the previous year. Net income attributable to the company reached JPY 17.1184 billion, a 9.8% increase from JPY 15.5904 billion in the same period last year. By business segment, net sales were as follows: Printing Business, JPY 123.9879 billion; Medical Business, JPY 27.7447 billion (approximately USD 1.743 billion); Imaging Business, JPY 55.2694 billion; and Industrial Business, JPY 14.5227 billion.

Ophthalmology

Eyewear Giant EssilorLuxottica Announces First-Half 2026 ResultsRevenue for the period amounted to €14.818 billion, compared to €14.023 billion in the same period last year, representing a year-on-year increase of 5.7%. Operating profit reached €2.751 billion, up from €2.532 billion in the previous year, a year-on-year increase of 8.7%. The Group’s net profit stood at €1.921 billion, compared to €1.799 billion in the same period last year, marking a year-on-year increase of 6.8%. In the second quarter, the Group’s revenue was €7.692 billion, compared to €7.175 billion in the same period last year. Among these figures, the Professional Solutions business generated revenue of €3.454 billion (approximately $4 billion), compared to €3.329 billion in the previous year. The Consumer Goods business reported revenue of €4.237 billion, compared to €3.846 billion in the same period last year.

Alcon Announces Second Quarter 2026 Results. Quarterly net sales and other revenues totaled $2.823 billion, compared to $2.596 billion in the same period last year. Quarterly operating profit was $11 million, compared to $247 million in the same period last year.

Bausch + Lomb Announces Second Quarter 2026 Results. Quarterly revenue amounted to $1.394 billion, compared to $1.278 billion in the same period last year. Quarterly operating profit was $83 million, versus an operating loss of $11 million in the same period last year. The net loss attributable to the company for the quarter was $14 million, compared to a net loss of $62 million in the same period last year.